Paloma Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Paloma Partners’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,775,000	Closed	-$1.36M	–	989
2023 Q1	$1.36M	Buy	+3,775,000	New	+$3.38M	0.05%	312
2022 Q2	–	Sell	-47,591	Closed	-$111K	–	1933
2022 Q1	$111K	Buy	+47,591	New	+$148K	﹤0.01%	1556
2019 Q2	–	Sell	-38,300	Closed	-$182K	–	2290
2019 Q1	$182K	Buy	38,300 +24,000	+168%	+$63K	﹤0.01%	1540
2018 Q4	$34K	Buy	+14,300	New	+$46.7K	﹤0.01%	1176
2017 Q3	–	Sell	-93,900	Closed	-$188K	–	2545
2017 Q2	$188K	Buy	+93,900	New	+$183K	﹤0.01%	2015

Other funds holding SRNE

SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return

KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

OAJ

Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TCOV

Trust Company of Vermont Brattleboro, Vermont $2.68B AUM

CFGS

Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Paloma Partners's SRNE Position: Q2 2023 in Review

Paloma Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 3,775,000 shares — an estimated $1.36M sold.

Paloma Partners first reported a position in SRNE in Q2 2017 and held it in 5 quarters. The position peaked at $1.36M in Q1 2023. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

Paloma Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
Paloma Partners sold 3,775,000 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $1.36M.
Paloma Partners first reported a position in Sorrento Therapeutics, Inc. in Q2 2017 and held it in 5 quarters.
Paloma Partners's Sorrento Therapeutics, Inc. position peaked at $1.36M in Q1 2023.
9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Paloma Partners's 13F filing for Q2 2023, filed 14 Aug 2023.